A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer
| Autor: | Daniel Morgensztern, D. Ross Camidge, Pier Paolo Scaglioni, Rachel Sorensen, Timothy F. Burns, Ariel Lopez-Chavez, Mitchell Keegan, Suresh S. Ramalingam, Ahmad Mouhamad Wehbe, David T. Weaver, David E. Gerber, Joanna Horobin, Ronan J. Kelly, David R. Spigel |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Cancer Research
integumentary system business.industry Mutant Phases of clinical research medicine.disease medicine.disease_cause Molecular biology respiratory tract diseases Focal adhesion Oncology Cancer stem cell Epidermal growth factor Cancer research Medicine KRAS business Lung cancer neoplasms Tyrosine kinase |
| Zdroj: | Journal of Clinical Oncology. 32:TPS8126-TPS8126 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | TPS8126 Background: KRAS mutations have been associated with poor prognosis in NSCLC and resistance to epidermal growth factor (EGFR) tyrosine kinase inhibitors. FAK represents a therapeutic target... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|